Abstract
The management of colorectal cancer peritoneal metastases is evolving. Traditionally, patients with limited liver or lung metastases were only considered as candidates for metastasectomy. However, patients with metastasis limited to the peritoneum were found to have improved clinical outcomes with metastasectomy [1]. Although systemic therapy significantly prolongs survival in patients with metastatic colorectal cancer, patients with PM demonstrated inferior outcomes. In the last 20 years, the recent advances in the form of CRS followed by HIPEC significantly prolonged survival in patients with colorectal peritoneal metastases with even cure reported in a selected group of patients [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ihemelandu CU, Shen P, Stewart JH, Votanopoulos K, Levine EA. Management of peritoneal carcinomatosis from colorectal cancer. Semin Oncol. 2011 Aug;38(4):568–75.
Bhatt A, Goéré D. Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal Cancer. Indian J Surg Oncol. 2016 Jun;7(2):177.
Klaver CEL, Musters GD, Bemelman WA, Punt CJA, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer [Internet]. 2015 May 24 [cited 2018 Feb 7];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492087/
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Apr 20;26(12):2013–9.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335–42.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003 Oct 15;21(20):3737–43.
Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumours: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108–15.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008 Sep;15(9):2426–2432.
Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS ONE [Internet]. 2015 [cited 2018 Feb 14];10(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380351/
Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol. 2016 Feb;7(1):72–8.
Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol Off J Eur Soc Med Oncol. 2002 Feb;13(2):267–72.
Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007 Jun;14(6):1818–24.
Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, et al. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol. 2008 Nov;15(11):3065–72.
Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015 Sep;22(9):2958–64.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ray, M.D. (2021). CRS and HIPEC for Peritoneal Metastasis from Colorectal Cancer. In: Ray, M.D. (eds) Multidisciplinary Approach to Surgical Oncology Patients. Springer, Singapore. https://doi.org/10.1007/978-981-15-7699-7_39
Download citation
DOI: https://doi.org/10.1007/978-981-15-7699-7_39
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-7698-0
Online ISBN: 978-981-15-7699-7
eBook Packages: MedicineMedicine (R0)